Advertisement

Topics

AveXis, Inc. Company Profile

12:10 EDT 22nd March 2019 | BioPortfolio

AveXis is a clinical-stage gene therapy company establishing unique industry alliances to create innovative treatments in areas of unmet medical needs. The company’s most advanced product candidate, ChariSMA, is in a fully-enrolled Phase 1 clinical trial for the treatment of spinal muscular atrophy (SMA), an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. SMA is the most common cause of infant mortality and is the second-most common autosomal recessive genetic disorder. For more information about AveXis, please visit: www.avexisbio.com.


News Articles [22 Associated News Articles listed on BioPortfolio]

@AveXisInc AveXis Inc.

ICYMI: @BioCentury details a @newdigsMIT pilot program to address portability of performance-based annuity contracts for potentially “curative therapies.” https://bit.ly/2GuOkCo 

Novartis pays 88% premium to gain control of AveXis

Novartis is making what it describes us a "bolt-on acquisition" for a cool US$8.7bn, acquiring Nasdaq-listed AveXis, a clinical-stage gene therapy developer

AveXis adds new jobs in gene therapy manufacturing expansion

More jobs and money are on the table for an AveXis plant in North Carolina, showing acquirer Novartis' interest in building out its gene therapy capabilities.

Novartis doubles investment in AveXis North Carolina site

In addition to the $55m previously invested, Novartis will spend a further $60m in expanding AveXisâ site in North Carolina enabling the manufacture of multiple gene therapies simultaneously.

Former Avexis Exec Kamal Named 4D Molecular Chief Technical Officer

Gene therapy developer 4D Molecular Therapeutics has appointed Fred Kamal to serve as chief technical officer. Kamal joins Emeryville, CA-based 4D Molecular from Avexis, where he was senior vice presi...

Novartis enters SMA race acquiring AveXis for US$8.7bn

Novartis doubles investment in AveXis gene therapy site

Dave Lennon was chosen by Novartis to run AveXis. Says they honestly haven’t internally finalized they price yet. #PLW2019pic.twitter.com/6cBTDoz089

Dave Lennon was chosen by Novartis to run AveXis. Says they honestly haven’t internally finalized they price yet. #PLW2019 pic.twitter.com/6cBTDoz089

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

AveXis, Inc.

AveXis is a clinical-stage gene therapy company establishing unique industry alliances to create innovative treatments in areas of unmet medical needs. The company’s most adv...

PBM Capital Group, LLC.

PBM Capital Group, LLC. is a private investment firm primarily focused on healthcare-related investments. Led by Paul Manning, a successful entrepreneur, PBM Capital partners w...

PBM Capital Group, LLC

PBM Capital Group, LLC. is a private investment firm primarily focused on healthcare investments. Led by Paul Manning, a successful entrepreneur, the PBM Capital Group partners...

More Information about "AveXis, Inc." on BioPortfolio

We have published hundreds of AveXis, Inc. news stories on BioPortfolio along with dozens of AveXis, Inc. Clinical Trials and PubMed Articles about AveXis, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AveXis, Inc. Companies in our database. You can also find out about relevant AveXis, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record